drip · manifesto

We built drip because a molecule should be as easy to launch as a t-shirt.

Every consumer brand built in the last decade picked from the same shelf. The serum in your bathroom, the supplement in your cabinet, the cream your favorite influencer shills. All formulated from the same commodity molecules. Matrixyl. GHK-Cu. BPC-157. The names change. The ingredients don't.

The people who actually discover new molecules (peptide labs, AI drug-design shops, academic synthesis groups) price for pharma, not for creators. A single novel peptide candidate costs tens of thousands of dollars to generate, months to validate, and years to commercialize. That math works when the buyer is Pfizer. It doesn't work when the buyer is a biohacker with 50,000 engaged followers and a story to tell.

So the consumer-wellness industry runs on a rental model. Brands license known actives, slap a story on top, and compete on marketing spend. The science is boring because the science is the same.

drip is the other way.

the thesis in three lines

1. AI can now generate novel, validated peptide candidates at near-zero marginal cost. 2. A creator with an audience can build a real brand around a molecule they own. 3. Every consumer peptide product should be genuinely new.

The rest of the platform (storefront, manufacturing, fulfillment, ads) is plumbing. Plumbing is solved. What isn't solved is giving the creator their own molecule.

what we're actually building

A platform where anyone describes a product in plain language, an AI discovery engine generates a peptide exclusive to them, the brand auto-generates, the storefront goes live, and first sales happen the same week. 60 minutes from idea to live store. 4 to 6 weeks from live store to shipped product.

The creator never writes a formula. Never signs a CMO contract. Never builds a Shopify theme. Never negotiates with an ad platform. They bring the audience and the taste. We bring the molecule and the rails.

We take 20% of sales. Tiered down to 10% after $1M lifetime. Creators keep 80-90% from the first order. Zero upfront, zero subscription, zero setup. The math works at one creator or a thousand.

why now

Three things converged in the last 18 months.

**Discovery got cheap.** Open-source models (ESM-2, RFdiffusion3, ProteinMPNN) plus proprietary refinements mean a laptop-scale GPU can screen 50,000 candidate sequences in a morning. Novel designs that cost pharma a million dollars cost a platform fifty.

**Pre-order infrastructure got mature.** Shopify + PreProduct + Stripe Connect + 3PL-with-API means a brand can launch with zero inventory, take pre-orders, manufacture on demand, and never touch a warehouse.

**RFK Jr. lifted the peptide ban.** Fourteen of the nineteen peptides banned from compounding since 2023 are returning to Category 1 in 2026. The gray-market vendors who monopolized the space lose their moat. A new wave of cosmetic-tier and research-tier brands is about to ship. We're building the rails they'll launch on.

Three curves crossed. The window to build the platform is 12 to 24 months before Shopify retrofits, before pharma notices, before the incumbent DTC platforms cargo-cult it. We plan to be the default.

why agents

Autonomous AI agents are starting to run commerce end-to-end. An agent with a budget, an API, and a goal can research a market, ship a product, buy ads, reply to customers, and adjust prices continuously at machine speed.

Every existing commerce platform treats agents as awkward users. Forms built for humans. Approvals built for humans. Rate limits built for humans. Agents end up scraping browsers, breaking on loading spinners, rate-limited into uselessness.

drip treats agents as first-class tenants from day one. Every action in the platform has a clean API. The MCP server exposes discovery, brand generation, storefront launch, ad spend, price adjustment, and customer replies as tools any Claude or GPT agent can call. Agents get their own smart-contract wallets on Solana, their own reputation scores, their own spend caps, their own sub-agent hierarchies. An agent launches a peptide brand the same way a human does. 60 minutes, same primitives, same terms.

This isn't a side quest. Agent-operated brands transact at orders-of-magnitude higher velocity than human brands. More tests, more variants, more pricing adjustments, more ad micro-bids, more customer interactions. The network density compounds. The commerce volume compounds. The token velocity compounds.

12 to 24 months is the window to build this agent-native before Shopify and BigCommerce retrofit. We're building in it.

the token

A quick note on $DRIP, because half our audience is crypto-native and half is not.

$DRIP is the internal currency of the platform. Every commerce swap, ad auction, synthesis slot, discovery API call, loyalty reward, prediction market, and agent-to-agent payment routes through it. It's engineered for velocity, not scarcity. The token moves constantly because useful things happen constantly. We project $20M to $28M in monthly on-chain volume from commerce alone at 1,000 active creators. Before speculation.

It is not a governance token. It is not a yield farm. It is not a vanity chip. It is the plumbing of a platform that is already cash-flowing. Hold it if you use the platform. Ignore it if you don't. Customers who buy products on creator storefronts pay in dollars and never see the token. Everything that matters to a non-crypto user happens in USD.

We'll deploy the token on Solana after the first 50 to 100 creators generate real GMV. We want the chart to be a reflection of the platform, not a substitute for it.

what we're not

We're not a pharma company. We don't make therapeutic claims. The content safety layer blocks any generated copy that steps over the cosmetic/drug line. Creators launching a brand on drip are selling cosmetic topicals and research-use compounds, not medicines. The regulatory path is well-trod. Every serious indie cosmetics brand uses it.

We're not a clinic. No telehealth MDs, no compounding pharmacies, no prescription tier. Those are separate companies solving a different problem. If a creator wants to launch a clinical brand, they use a different platform. We focus on what we're best at.

We're not a DeSci science funding pool. drip doesn't fund research. drip turns research output into revenue. The commerce layer is what keeps the science cycle paying for itself. That's the part no DeSci project has solved yet. We think it's the missing piece.

We're not trying to be Shopify. Shopify has a better theme editor, a bigger app ecosystem, and a deeper enterprise sales force. They can have all three. drip is vertical. We go deep on one category, peptides, and win on molecule discovery, not on generic DTC plumbing.

how it goes

One creator, one product, one contract manufacturer, one channel, one geography. That's v0.1. Prove the 60-minute funnel with real dollars. Nothing widens until the current slice produces revenue.

Then we add creators. Then we add the agent API. Then we add the token. Then we add prediction markets and backing markets and the full commerce flywheel. Each addition earns its place by being profitable on its own.

We don't need to raise to do this. We don't need to burn capital to bootstrap demand. Creators bring their audience. We are a multiplier on their existing reach, not a substitute for it. Zero inventory, zero upfront cost, zero operational drag. The unit economics work at one creator and compound at a thousand.

join

Beta creators: we're taking a small number before public launch. If you have an audience, a taste for peptide products, and a brand concept you're willing to put your name behind, reach out. The first ten creators are shaping the platform.

Agent builders: the API is in design now. OpenAPI spec and MCP server land in week 4. If you're building an autonomous commerce agent and want to run it on peptide brands, this is the rail.

Everyone else: drip.markets. Waitlist. We'll ship the first stores within 90 days.

the molecule is the product. the creator is the brand. drip is the rails.